Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Top Cited Papers
Open Access
- 1 February 2017
- Vol. 168 (4), 707-723
- https://doi.org/10.1016/j.cell.2017.01.017
Abstract
No abstract availableKeywords
Funding Information
- NIH/NCI (R01 CA1633793, R35 CA197633, P01 CA168585)
- Cancer Prevention Research in Texas (RP120108)
- Cancer-Cancer Research Institute Cancer Immunology Dream Team Translational Research (SU2C-AACR-DT1012)
This publication has 181 references indexed in Scilit:
- Low Dose Decitabine Treatment Induces CD80 Expression in Cancer Cells and Stimulates Tumor Specific Cytotoxic T Lymphocyte ResponsesPLOS ONE, 2013
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationNew England Journal of Medicine, 2011
- A clinical microchip for evaluation of single immune cells reveals high functional heterogeneity in phenotypically similar T cellsNature Medicine, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumorsProceedings of the National Academy of Sciences, 2010
- Anti-CD73 antibody therapy inhibits breast tumor growth and metastasisProceedings of the National Academy of Sciences, 2010
- TGFβ in CancerCell, 2008
- Abrogation of TGFβ Signaling in Mammary Carcinomas Recruits Gr-1+CD11b+ Myeloid Cells that Promote MetastasisCancer Cell, 2008
- Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunityNature Reviews Immunology, 2004
- Cancer immunoediting: from immunosurveillance to tumor escapeNature Immunology, 2002